# Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial

> **NCT00272480** · PHASE2,PHASE3 · COMPLETED · sponsor: **Imperial College London** · enrollment: 16 (actual)

## Conditions studied

- HTLV-I-associated Myelopathy

## Interventions

- **DRUG:** Zidovudine/lamivudine
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT00272480
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11-08
- **Primary completion:** 2002-07-30
- **Final completion:** 2002-07-30
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272480, "Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00272480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*